238 related articles for article (PubMed ID: 34082425)
21. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
Bousquet J; Bachert C; Bernstein J; Canonica GW; Carr W; Dahl R; Demoly P; Devillier P; Hellings P; Fokkens W; Klimek L; Lieberman P; Meltzer E; Price D; Ryan D; Wahn U
Expert Opin Pharmacother; 2015 Apr; 16(6):913-28. PubMed ID: 25747125
[TBL] [Abstract][Full Text] [Related]
22. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
Klimek L; Bousquet J; Price D
Expert Opin Drug Saf; 2016 Jan; 15(1):117-29. PubMed ID: 26581312
[TBL] [Abstract][Full Text] [Related]
23. Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort.
Stjarne P; Strand V; Theman K; Ehnhage A
Rhinology; 2019 Aug; 57(4):279-286. PubMed ID: 30938376
[TBL] [Abstract][Full Text] [Related]
24. Real-Life Effectiveness of MP-AzeFlu (Dymista
Stjärne P; Nguyen DT; Kuhl HC
Pragmat Obs Res; 2023; 14():1-11. PubMed ID: 36628265
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of in vitro Penetration of Fluticasone Propionate from MP-AzeFlu and Fluticasone Propionate Nasal Spray Through EpiAirway™606 Tissues Using Vertical Diffusion Cells.
Berger WE; Bachert C; Allara R; Koltun A; Kopietz F; Maus JG; D'Addio AD
J Asthma Allergy; 2020; 13():187-192. PubMed ID: 32547111
[TBL] [Abstract][Full Text] [Related]
26. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study.
Klimek L; Bachert C; Stjärne P; Dollner R; Larsen P; Haahr P; Agache I; Scadding G; Price D
Allergy Asthma Proc; 2016 Sep; 37(5):376-86. PubMed ID: 27657521
[TBL] [Abstract][Full Text] [Related]
27. An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu
Marth K; Renner A; Langmayr G; Pohl W; Nguyen DT; Kuhl HC
Drugs Real World Outcomes; 2024 Jun; 11(2):231-240. PubMed ID: 38351402
[TBL] [Abstract][Full Text] [Related]
28. Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey.
Canonica GW; Klimek L; Acaster S; Dollner R; Kaulsay R; Lo SH; Price DB; Scadding GK; Valovirta E; Zieglmayer P
Curr Med Res Opin; 2021 Jul; 37(7):1259-1272. PubMed ID: 33840316
[TBL] [Abstract][Full Text] [Related]
29. Effects of H1 antihistamine addition to intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis.
Seresirikachorn K; Chitsuthipakorn W; Kanjanawasee D; Khattiyawittayakun L; Snidvongs K
Int Forum Allergy Rhinol; 2018 Oct; 8(10):1083-1092. PubMed ID: 29917324
[TBL] [Abstract][Full Text] [Related]
30. Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma.
Price D; Klimek L; Gálffy G; Emmeluth M; Koltun A; Kopietz F; Nguyen DT; van Weissenbruch R; Pohl W; Kuhl HC; Scadding G; Mullol J
Clin Mol Allergy; 2020; 18():15. PubMed ID: 32782442
[TBL] [Abstract][Full Text] [Related]
31. Azelastine and fluticasone nasal spray: any advantage?
Drug Ther Bull; 2014 Feb; 52(2):21-4. PubMed ID: 24504481
[TBL] [Abstract][Full Text] [Related]
32. A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
Ridolo E; Montagni M; Melli V; Bonzano L; Incorvaia C; Canonica GW
Ther Deliv; 2015; 6(6):653-9. PubMed ID: 25913181
[TBL] [Abstract][Full Text] [Related]
33. Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups.
Berger WE; Fineman SM; Lieberman P; Miles RM
Ann Allergy Asthma Immunol; 1999 Jun; 82(6):535-41. PubMed ID: 10400480
[TBL] [Abstract][Full Text] [Related]
34. MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis.
van Weissenbruch R; Klimek L; Gálffy G; Emmeluth M; Koltun A; Kopietz F; Nguyen DT; Kuhl HC; Pohl W; Scadding GK; Price D; Mullol J
J Asthma Allergy; 2020; 13():633-645. PubMed ID: 33293835
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care.
De Jong HJI; Voorham J; Scadding GK; Bachert C; Canonica GW; Smith P; Wahn U; Ryan D; Castillo JA; Carter VA; Murray RB; Price DB
World Allergy Organ J; 2020 Dec; 13(12):100490. PubMed ID: 33376573
[TBL] [Abstract][Full Text] [Related]
36. A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu.
Dollner R; Lorentz Larsen P; Dheyauldeen S; Steinsvåg S
Allergy Rhinol (Providence); 2017 Oct; 8(3):148-156. PubMed ID: 29070272
[TBL] [Abstract][Full Text] [Related]
37. Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis.
Scadding G; Bousquet J; Bachert C; Fokkens WJ; Hellings PW; Prokopakis E; Pfaar O; Price D
Rhinology; 2019 Feb; 57(1):49-56. PubMed ID: 30052697
[TBL] [Abstract][Full Text] [Related]
38. Treatment with azelastine hydrochloride and fluticasone propionate in a single delivery device of young children and adolescents with allergic rhinitis.
Berger WE; Mustakov TB; Kralimarkova TZ; Christoff G; Popov TA
Allergy Asthma Proc; 2020 Jul; 41(4):232-239. PubMed ID: 32605694
[No Abstract] [Full Text] [Related]
39. Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers.
Roca-Ferrer J; Pujols L; Pérez-González M; Alobid I; Callejas B; Vicens-Artés S; Fuentes M; Valero A; Picado C; Castor D; Nguyen D; Mullol J
Allergy Asthma Clin Immunol; 2018; 14():86. PubMed ID: 30574167
[TBL] [Abstract][Full Text] [Related]
40. Intranasal antihistamine is superior to oral H
Du K; Qing H; Zheng M; Wang X; Zhang L
Ann Allergy Asthma Immunol; 2020 Nov; 125(5):589-596.e3. PubMed ID: 32650045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
